Cargando…
Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis
A major challenge for successful immunotherapy against glioma is the identification and characterization of validated targets. We have taken a bioinformatics approach towards understanding the biological context of IL-13 receptor α2 (IL13Rα2) expression in brain tumors, and its functional significan...
Autores principales: | Brown, Christine E., Warden, Charles D., Starr, Renate, Deng, Xutao, Badie, Behnam, Yuan, Yate-Ching, Forman, Stephen J., Barish, Michael E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3800130/ https://www.ncbi.nlm.nih.gov/pubmed/24204956 http://dx.doi.org/10.1371/journal.pone.0077769 |
Ejemplares similares
-
Adoptive transfer of IL13Rα2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARs
por: Brown, Christine E, et al.
Publicado: (2013) -
Clinical development of IL13Rα2-targeting CAR T cells for the treatment of glioblastoma
por: Brown, Christine E, et al.
Publicado: (2015) -
Cytokine Induction of VCAM-1 but Not IL13Rα2 on Glioma Cells: A Tale of Two Antibodies
por: Mahadev, Vaidehi, et al.
Publicado: (2014) -
Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma
por: Barish, Michael E., et al.
Publicado: (2022) -
Correction: Glioma IL13Rα2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis
Publicado: (2018)